Longsworth Todd Christopher
SEC CIK 1693530 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVCR | NovoCure Ltd | GC | 62.5K | — | $384.4K | 3 | 2021-07-06 | 2022-03-08 |
Most active insiders at NVCR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | DOYLE WILLIAM F | Executive COB, Dir | — | $933.1K |
| 2 | Leonard Frank X | EVP, Pres, Novocure Oncology | — | $919.8K |
| 3 | Paravasthu Mukund | COO | — | $693.8K |
| 4 | Weinberg Uri | Chf Medical, Innovation Ofr | — | $232.2K |
| 5 | Brackmann Christoph | CFO | — | $85.3K |
| 6 | Stafford Kristin | Dir | — | $46.4K |
| 7 | Ocean Allyson J | Dir | — | $46.4K |
| 8 | Scannell Timothy J | Dir | — | $46.4K |
| 9 | VERNON W ANTHONY | Dir | — | $46.4K |
| 10 | Hung David | Dir | — | $46.4K |
Longsworth Todd Christopher made no open-market trades at NVCR in the last 12 months.
Transactions 3
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-09 | 2022-03-08 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | GC | S - Sale | $70.10 | -2,339 | 62.5K | -4% | -$164.0K | |
| DM | 2022-03-07 | 2022-03-03+ | NVCR | NovoCure Ltd | Longsworth Todd Christopher | GC | S - Sale | $71.87 | -3,067 | 66.8K | -4% | -$220.4K |
| 2021-07-08 | 2021-07-06 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | GC | A - Grant | $137.12 | +154 | 67.9K | +0.2% | +$21.1K |
Purchase Sale Sale after option exercise All abbreviations